Companies › Connect Biopharm
1 active drug program in 1 registered trial: 1 Phase 2; Respiratory; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Rademikibart (CBP-201) Type 2 inflammation modulator | – | Phase 2 | Asthma Acute | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07705737 | Rademikibart (CBP-201) | Phase 2 | Asthma Acute | Respiratory | Dec 2026 |
No annotated target.
–
Aqualung Therapeutics Upstream Bio PPD Development, LP Shanghai Mabgeek Biotech.Co.Ltd Uniquity One (UNI)
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.